Hemp-Derived Cannabinoids at a Crossroads: Regulation, Growth, and What's Next

As the supplement industry approaches a pivotal deadline for hemp-derived cannabinoid products, a look back at recent coverage offers context for how the sector arrived at this moment—and what's at stake for manufacturers.

What Deadline Is the Industry Facing Right Now?

A recent feature outlined the federal THC cap set to take effect this year, which would limit hemp products to 0.3% total tetrahydrocannabinols, or 0.4 mg of total THC per container.¹ According to Jonathan Miller, general counsel for the US Hemp Roundtable, that threshold "would ban 95% of products currently on the market." A continuing resolution passed by the Senate in early August could push the implementation date from November 12 to December 11, 2026, offering brands a brief reprieve, though the underlying uncertainty remains.

How Did This THC Cap Come About?

That looming deadline traces back to legislative action from late 2025. After the longest government shutdown in U.S. history, the Senate passed the FY26 Agriculture Appropriations Bill, which included a provision, led by Senator Mitch McConnell, redefining hemp and establishing the THC limits now facing the industry.² Hemp and cannabis trade groups, including the US Hemp Roundtable and NORML, publicly opposed the measure, warning it could undercut industry growth and consumer choice.

What Regulatory Gaps Led to This Point?

That 2025 vote did not emerge in a vacuum. Years of regulatory ambiguity preceded it. Following the 2018 Farm Bill's removal of hemp from the Controlled Substances Act, the FDA declined in January 2023 to create a dedicated regulatory pathway for CBD in foods and supplements, leaving the market largely self-governed.³ Subsequent legislative efforts, including the Hemp Access and Consumer Safety Act and the Cannabinoid Safety and Regulation Act, aimed to close that gap but stalled, while proposals like the 2024 "Mary Miller amendment" threatened to eliminate the large majority of hemp-derived cannabinoid products entirely.

How Has the Industry Tried to Regulate Itself?

Absent consistent federal rules, parts of the industry have pursued self-regulation. In 2024, the U.S. Hemp Authority launched an Adult Use Hemp Product Certification Program aimed specifically at delta-8 and delta-9 THC products, using a third-party auditor to verify compliance.⁴

What’s the Commercial Scale of What’s at Stake?

The commercial stakes underlying these regulatory battles are significant. One market report cited estimated the global hemp-derived CBD market at $8.28 billion in 2023, projecting growth to $46.25 billion by 2034—driven substantially by rising use in personal care and cosmetics.⁵ That trajectory underscores why THC-cap proposals may be viewed as consequential rather than incremental for manufacturers.

Is Ingredient Innovation Continuing Despite the Uncertainty?

Meanwhile, ingredient innovation has continued alongside the regulatory turbulence. Nonpsychoactive cannabinoids such as CBN, CBG, CBDA, and THCV are drawing formulator interest for applications in sleep, pain, cognitive, and metabolic health products.⁶ One study of a proprietary CBN ingredient found reductions in sleep disturbance scores, with improvements in sleep quality comparable to or better than those seen with melatonin. Older adults have emerged as a particularly fast-growing group turning to these cannabinoids, primarily seeking support for sleep and pain, while women and consumers with chronic conditions or nervous system disorders are also increasingly cited as populations that may benefit from nonpsychoactive cannabinoid formulations. Companies like FloraWorks have pursued New Dietary Ingredient Notifications and toxicology studies to build a stronger regulatory foundation for these ingredients, even as manufacturing standards across the category remain inconsistent.

What Does This Mean for Manufacturers Going Forward?

Taken together, this coverage traces a throughline from years of regulatory gray area to the current THC-cap deadline, while highlighting the market growth and product innovation that give the debate its urgency for supplement manufacturers.

References

1. McEvoy E. How Washington's next move could reshape the cannabinoid supplement industry. Nutritional Outlook. August 13, 2026. Accessed August 14, 2026. https://www.nutritionaloutlook.com/view/how-washington-could-reshape-cannabinoid-supplement-industry
2. Colli M. US government shutdown ends with redefinition of hemp. Nutritional Outlook. November 17, 2025. Accessed August 14, 2026. https://www.nutritionaloutlook.com/view/us-government-shutdown-ends-with-redefinition-of-hemp
3. McEvoy E. In the weeds: an update on the hemp regulatory landscape. Nutritional Outlook. 2024;27(8). October 14, 2024. Accessed August 14, 2026. https://www.nutritionaloutlook.com/view/in-the-weeds-an-update-on-the-hemp-regulatory-landscape
4. Colli M. US Hemp Authority unveil new adult use delta-9-THC and delta-8-THC certificate program. Nutritional Outlook. October 18, 2024. Accessed August 14, 2026. https://www.nutritionaloutlook.com/view/us-hemp-authority-unveil-new-adult-use-delta-9-thc-and-delta-8-thc-certificate-program
5. Colli M. 2025 hemp-derived CBD market report showcases rising interest in CBD. Nutritional Outlook. January 8, 2025. Accessed August 14, 2026. https://www.nutritionaloutlook.com/view/2025-hemp-derived-cbd-market-report-showcases-rising-interest-in-cbd
6. McEvoy E. How nonpsychoactive cannabinoids can shape functional health. Nutritional Outlook. 2025;28(8). October 14, 2025. Accessed August 14, 2026. https://www.nutritionaloutlook.com/view/how-nonpsychoactive-cannabinoids-can-shape-functional-health